false
0001875558
0001875558
2025-09-22
2025-09-22
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
September 22, 2025
Nuvectis Pharma, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware
(State or Other Jurisdiction
of Incorporation) |
|
001-41264
(Commission File Number) |
|
86-2405608
(IRS Employer Identification No.) |
1 Bridge Plaza Suite 275
Fort Lee, NJ 07024
(Address of Principal Executive Offices)
(201) 614-3150
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the
Exchange Act:
| Title of Class |
Trading Symbol(s) |
Exchange Name |
| Common Stock |
NVCT |
Nasdaq Capital Market |
| ¨ |
Written communications pursuant to Rule 425 under the Securities Act. |
| |
|
| ¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act. |
| |
|
| ¨ |
Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act. |
| |
|
| ¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers. |
On September 22, 2025, the
Board of Directors (the “Board”) of Nuvectis Pharma, Inc. (the “Company”) appointed Juan Sanchez, MD, to the Board.
Dr. Sanchez will serve as a director until his term expires at the 2026 annual meeting of stockholders, at which time he will stand for
election by the Company’s stockholders.
Dr. Sanchez has (i) no arrangements
or understandings with any other person pursuant to which he was appointed to as a director, and (ii) no family relationship with any
director or executive officer of the Company or any person nominated or chosen by the Company to become a director or executive officer.
Dr. Sanchez has no direct or indirect material interest in any transaction
or series of similar transactions contemplated by Item 404(a) of Regulation S-K.
The Company announced Dr.
Sanchez’s appointment via press release on September 25, 2025. A copy of the press release is being filed as Exhibit 99.1 and incorporated
by reference herein.
| Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits.
The following exhibit is furnished herewith:
| Exhibit |
|
|
| Number |
|
Description |
| 99.1 |
|
Press release issued by Nuvectis Pharma, Inc., dated September 25, 2025. |
| 104 |
|
Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
| |
Nuvectis Pharma, Inc. |
| |
(Registrant) |
| |
|
|
| Date: September 25, 2025 |
|
|
| |
|
|
| |
By: |
/s/ Ron Bentsur |
| |
|
Ron Bentsur |
| |
|
Chairman, Chief Executive Officer and President |
